IL-1β, IL-6, TNF-α, and CRP were previously evaluated for their potential to be therapeutic targets for anti-inflammatory treatment in atherosclerosis, thus reducing the residual risk of atherosclerotic cardiovascular disease [12]. Here, TNF is linked to atherosclerosis.